Arrowhead Pharmaceuticals
Manufacturing · California, United States · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
177 E Colorado Blvd Ste 700, Pasadena, C...Phone Number
(626) 304-3400Website
www.arrowheadpharma.comRevenue
$669.5 MillionStock Symbol
ARWRIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
2
1
2
1
1
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowheads RNAi-based therapeutics leverage this natural pathway of gene silencing.Explore more
Arrowhead Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Arrowhead Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Arrowhead Pharmaceuticals launches new products
Funding: Get notified immidiatlly once Arrowhead Pharmaceuticals has new funding data
Click to see if Arrowhead Pharmaceuticals had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Check out if Arrowhead Pharmaceuticals is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Arrowhead Pharmaceuticals
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Arrowhead Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Arrowhead Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Arrowhead Pharmaceuticals recently announced quarterly report
Recommended Actions
Find VP level buyers at Arrowhead Pharmaceuticals
Find 2 more new buyers
Compare Similar Companies to Arrowhead Pharmaceuticals
Compare insights from companies similar to Arrowhead Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Arrowhead Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Arrowhead Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Arrowhead Pharmaceuticals.
Arrowhead Pharmaceuticals financials insights
Gather financial insights about Arrowhead Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2024
Debt
$500M
Arrowhead Pharmaceuticals Tech Stack
A closer look at the technologies used by Arrowhead Pharmaceuticals
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Event
Product Marketing, Events, Business Intelligence, Analytics & Insights, Sales, Pharmaceuticals, Field /Outside Sales, Field Marketing, Operations, Sales Enablement, Sales Operations
Open Position
Open Position
Hiring Plans
Hiring Plans
Arrowhead Pharmaceuticals News & Media
Arrowhead Pharmaceuticals Q3 Earnings Call Highlights
Arrowhead Pharmaceuticals (NASDAQ:ARWR) reported positive Phase III results for plozasiran in severe hypertriglyceridemia (SHTG), accelerating plans for a supplemental New Drug Application and highlighting continued growth in the launch of its REDEMPLO therapy for familial chylomicronemia syndrome (Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses Cardiometabolic Pipeline and Clinical Development Programs Transcript
Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses Cardiometabolic Pipeline and Clinical Development Programs June 29, 2026 11:30 AM EDTCompany...Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Prepared Remarks Transcript
Arrowhead Pharmaceuticals, Inc. (ARWR) Goldman Sachs 47th Annual Global Healthcare Conference 2026 June 10, 2026 9:00 AM EDTCompany ParticipantsVincent...Arrowhead Pharmaceuticals Lines Up SHASTA Readout as REDEMPLO Launch Gains Traction
Arrowhead Pharmaceuticals (NASDAQ:ARWR) executives outlined upcoming clinical catalysts, early commercial trends and pipeline priorities during a Jefferies fireside chat, with Chief Medical Officer James Hamilton emphasizing that the company remains focused exclusively on siRNA therapeutics through
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Arrowhead Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mech... Read More
